Clinical effect of aribulin combined with NP regimen in the treatment of patients with advanced breast cancer
- VernacularTitle:艾立布林联合NP方案治疗晚期乳腺癌患者的临床效果
- Author:
Linna WANG
1
;
Di WANG
;
Yanhong DONG
Author Information
- Publication Type:Journal Article
- Keywords: breast neoplasms; vinorelbine; cisplatin; vascular endothelial growth factors; Eribulin; clinical benefit rate
- From: Tianjin Medical Journal 2025;53(3):326-330
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the clinical effect of aribulin combined with vinorelbine+cisplatin(NP)regimen in the treatment of advanced breast cancer patients.Methods Eighty patients with advanced breast cancer were selected and divided into the conventional group(treated with chemotherapy using NP regimen)and the combined group(treated with aribulin combined with NP regimen),with 40 cases in each group.The clinical benefit rate(CBR),objective response rate(ORR)and overall efficacy of the two groups were compared.Patients were followed for 12 months.The progression-free survival(PFS)was recorded in the two groups of patients.Serum levels of vascular endothelial growth factor(VEGF)A,VEGFB and VEGFC before treatment and 4 cycles after treatment were detected by enzyme-linked immunosorbent assay(ELISA).Adverse reactions of patients were evaluated and graded according to common adverse event evaluation criteria.Results The ORR and CBR of the combined group were significantly higher than those of the conventional group,and the overall curative effect of the combined group was better than that of the conventional group(P＜0.05).PFS in the combination group was longer than that in the conventional group(P＜0.01).After treatment,the levels of VEGFA,VEGFB and VEGFC in the 2 groups were lower than those before treatment,and the levels in the combined group were significantly lower than those in the conventional group(P＜0.05).The main adverse reactions of 2 groups during treatment were grade Ⅰto Ⅱ,including neutropenia,gastrointestinal reaction,peripheral nerve abnormality,fatigue,liver function injury and alopecia,with no statistical significance.Conclusion Aribulin combined with NP regimen in the treatment of advanced breast cancer can increase CBR and decrease VEGF expression level,with good safety.
